Zuma

We're building the future of AI compute at Graphcore, where our team of semiconductor, software and AI experts is creating the complete AI compute stack from silicon to datacenter infrastructure. We developed the Intelligence Processing Unit (IPU), a groundbreaking processor specifically designed for machine intelligence that delivers leading-edge AI performance with unprecedented efficiency. Our silicon engineers are doing pioneering work, including being the first company in the world to bring a Wafer-on-Wafer AI processor to market, while our software and AI teams build new tools and optimize popular AI models to lead the market for performance, efficiency, and usability. We're optimistic about a future where people live healthier, fairer, more informed, and more sustainable lives. Our AI technology aims to bring democratized intelligence that everyone can benefit from. Now as a wholly owned subsidiary of SoftBank Group, backed by significant long-term investment, we're expanding our teams around the world to solve the toughest problems in AI computing. We're bringing together the brightest minds in a place where everyone has the opportunity to make an impact on the company, our products, and the future of artificial intelligence.

In 2023, a group of visionary scientists and investors recognized that drug discovery remained an expensive, time-consuming process with high failure rates. Despite advances in AI, the pharmaceutical industry was still struggling to translate computational insights into viable medicines. This realization sparked the creation of Xaira Therapeutics - co-founded and incubated by ARCH Venture Partners and Foresite Labs - to build an integrated biotechnology company that would truly harness the transformative power of artificial intelligence for drug discovery. Built on the groundbreaking protein design work of Nobel Laureate Dr. David Baker and his team at the University of Washington's Institute for Protein Design, Xaira brings together advanced AI research, expansive data generation, and robust therapeutic product development. The company emerged from stealth mode in 2024 with over $1 billion in funding, ready to revolutionize how we treat disease by making predictions about the right biology to target, the best therapeutics to modulate those targets, and the patients who will benefit most. With offices in South San Francisco, Seattle, and London, Xaira is shifting drug discovery from an empirical science to a precise engineering discipline.

Chai Discovery builds AI foundation models designed to predict and reprogram biochemical molecular interactions, with the goal of transforming drug discovery into an engineering discipline. The company's founders are researchers who co-invented protein language modeling and developed state-of-the-art protein folding algorithms. Chai Discovery is backed by OpenAI, Thrive Capital, and General Catalyst, and has a partnership with Eli Lilly. The company's core platform - anchored by its Chai-1 and Chai-2 models - predicts and redesigns interactions between biochemical molecules at atomic precision. Key capabilities include drug-like antibody design against challenging targets and the generation of functional GPCR agonists with minimal screening. The platform has reported a success rate of over 85% for computationally designed molecules meeting drug-like properties, a figure that contrasts with the traditional approach of screening millions or billions of protein sequences over years at a cost of billions of dollars. Chai Discovery's technical work spans several domains: Protein language modeling and folding algorithms Computational protein and antibody design GPCR agonist design Biopharma-focused machine learning Computational prediction of biochemical interactions The company focuses on targets traditionally considered undruggable, positioning its platform as a tool capable of addressing therapeutic challenges that conventional methods cannot efficiently reach.

Protogon Research builds autonomous AI systems and deploys them directly into financial markets through proprietary trading. The company's stated mission is to develop the most intelligent AI systems in the world, using trading as a practical testbed for AI that genuinely understands the world - rather than one that simply replicates human behaviour or produces superficial outputs. Its long-term research aim is to chart a path toward superintelligence. The company was founded by Rafael Cosman, a serial entrepreneur who previously co-founded Archblock and the TrueFi DeFi protocol. Protogon Research is backed by Zelda Ventures, OVO, and StartX, and is a member of the NVIDIA Inception Program. Protogon's technical work spans machine learning, AI research, trading, and operations. The company describes its technology as original, proprietary, and defensible, and positions itself deliberately apart from traditional quantitative trading firms: the priority is building lasting, transformative AI systems rather than optimising for short-term trading profits. The team is described as highly technical, with deep expertise across its core domains.

OpenEvidence is an AI-powered medical information platform built for healthcare professionals making clinical decisions at the point of care. Its core product functions as an AI copilot for physicians: clinicians submit clinical questions and receive evidence-based answers, synthesised from trusted medical literature and accompanied by references. The platform is available free to verified U.S. healthcare professionals. The platform has reached considerable scale within the U.S. medical community. More than 40% of U.S. physicians log in daily, and the platform has supported over 100 million AI-powered clinical consultations from doctors and frontline clinicians. OpenEvidence draws on partnerships with leading medical institutions and is designed for use across practice settings, from major hospital systems to rural clinics. The company operates at the intersection of several technical disciplines, including: Natural language processing applied to medical literature Clinical decision support and medical knowledge synthesis HIPAA-compliant health IT infrastructure Evidence-based AI for high-stakes clinical environments OpenEvidence is focused on the United States market and positions itself as a foundational layer for how physicians access and apply medical knowledge in practice.

d-Matrix is a computing hardware company founded in 2019 that designs and builds purpose-built platforms for running generative AI inference at scale. Rather than adapting existing GPU architectures, the company built its platform from the ground up, using digital in-memory compute technology to address a core bottleneck in AI workloads: the costly and energy-intensive movement of data between memory and processors. Its flagship product, Corsair, is a computing platform engineered specifically for the demands of generative AI inference. By processing data closer to where it is stored, Corsair is designed to deliver ultra-low latency and high throughput while keeping energy consumption and operational costs manageable - performance characteristics that are increasingly important as generative AI deployments scale. The company sits at the intersection of silicon design, systems engineering, and software, working across the full stack to optimise compute architecture for inference. Its technical domains include: AI inference and generative AI Digital in-memory compute Compute architecture and silicon design Energy-efficient, high-throughput, low-latency systems Systems engineering and software Founded with a mission to make generative AI commercially viable and sustainable beyond the largest technology companies, d-Matrix has grown from a small startup to a team of over 200 engineers and technologists. The company operates with a first-principles approach, taking on fundamental hardware problems rather than incremental adaptations of existing infrastructure.